Probiotics Supplementation for Improving Glucolipid Parameters in Individuals with Prediabetes: A Systematic Review and Meta-Analysis of Randomized Trials

Probiotics and Antimicrobial Proteins, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 14, 2025

Language: Английский

---

Beta-cell preservation in T2DM using a pathophysiologic approach

Postgraduate Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: April 17, 2025

Type 2 diabetes and obesity rates continue to rise. affects 1-2 million new individuals annually. Despite a wide range of treatment options for type many people still fail achieve therapeutic goals. Treating more proactively with pathophysiologic approach can ensure higher success reduce complications. This article summarizes the progressive understanding pathophysiology diabetes, draws connection between illness beta-cell health, introduces its focus on preservation. compiled clinical data, evidence-based medicine, experimental results create one comprehensive narrative review.

Language: Английский

---

Antidiabetic combination therapy and cardiovascular outcomes: An evidence-based approach

World Journal of Diabetes, Journal Year: 2025, Volume and Issue: 16(4)

Published: Feb. 28, 2025

Type 2 diabetes mellitus is associated with a 2-4 times increased risk of cardiovascular (CV) disease. Glucagon-like polypeptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) are two important classes drugs CV benefits independent their antihyperglycemic efficacy. The outcome trials both GLP1RA SGLT2i have demonstrated superiority/neutrality concerning major adverse events (MACE). While GLP1RAs exhibited significant reduction in ischemic stroke myocardial infarction (MI), uniformly hospitalization for heart failure (HF) as class effect. unique clinical the distinct but complementary mechanisms action make combination these mechanistically sound one. Recent meta-analyses suggest an additive benefit therapy GLP1RA/SGLT2i vs monotherapy. Zhu et al, recent issue World Journal Diabetes, demonstrates numerically lower hazard ratio (HR) outcomes monotherapy either agent, MACE compared to alone [HR = 0.51, 95% confidence interval (CI): 0.16-1.65], or (HR 0.48, 95%CI: 0.15-1.54). death rate was also 0.58, 0.08-3.39), 0.55, 0.07-3.25). Fatal non-fatal MI fatal were reduced 0.45, 0.10-2.18 HR 0.86, 0.12-6.23, respectively), 0.44, 0.09-2.10 0.74, 0.10-5.47, respectively). Hospitalization HF prevented 0.26, 0.03-1.88), 0.33, 0.04-2.53). They that may not provide improvement recurrent patients prior HF, proposing role this subgroup. Appropriate patient selection vital optimize well cost-effectiveness therapy.

Language: Английский

---

Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis

World Journal of Diabetes, Journal Year: 2025, Volume and Issue: 16(4)

Published: Feb. 28, 2025

Despite therapeutic benefits, discontinuation of tirzepatide is common in randomized controlled trials (RCTs) due to adverse events (AEs) and other causes. No previous systematic reviews have explored the reasons for discontinuing RCTs. To explore permanent vs controls [placebo, insulin, glucagon-like peptide-1 receptor agonists (GLP-1Ras)] Relevant RCTs were systematically searched using related terms through multiple databases such as MEDLINE (via PubMed), Scopus, Cochrane Central Register, ClinicalTrials.gov from their inception until June 20, 2024. RevMan web was used conduct meta-analysis random-effects models. Outcomes presented risk ratios (RR) with 95% confidence intervals (CI). Seventeen (n = 14645), mostly having low risks bias, analyzed. Compared placebo, study drug substantially lower 10 mg (RR: 0.69, 95%CI: 0.51-0.93, P 0.02) similar 5 0.74, 0.47-1.17, 0.20) 15 0.94, 0.68-1.31, 0.71). Tirzepatide had identical when compared insulin at 0.96, 0.75-1.24, 0.77) 1.19, 0.77-1.82, 0.44) doses, whereas higher than 1.31, 1.03-1.67, 0.03). GLP-1RA, 0.98, 0.70-1.37, 0.90) but 1.40, 1.03-1.90, 0.03) 1.70, 1.27-2.27, 0.0004). Tirzepatide, all AE-related insulin; only greater doses placebo or GLP-1RA. Discontinuation withdrawal by subjects insulin. (all doses) conferred a causes not specifically mentioned. The group arm. Many factors AEs led included

Language: Английский

---

Highlights of the current issue

Diabetes & Metabolic Syndrome Clinical Research & Reviews, Journal Year: 2024, Volume and Issue: 18(6), P. 103084 - 103084

Published: June 1, 2024

Language: Английский

---

Role of intestinal glucagon-like peptide-1 in hypoglycemia response impairment in type 1 diabetes

World Journal of Diabetes, Journal Year: 2024, Volume and Issue: 15(11), P. 2237 - 2241

Published: Oct. 16, 2024

This study critically examines the novel findings presented by Jin

Language: Английский

---